Sandra A. Boyd

FDA investigator

Appears on 16 documents from 2019 to 2026, most often at sites in India. Most often cites control of microbiological contamination (21 CFR 211.113).

16
Documents on file
7.3
Observations per 483
2019
First seen
2026
Most recent

What they cite most

From 115 observations

Activity by year

2019: 1, 2020: 1, 2021: 2, 2022: 4, 2023: 4, 2024: 1, 2025: 2, 2026: 1

Where

India 6 · Indiana 2 · China 1 · France 1 · Illinois 1 · Malaysia 1

Is Sandra A. Boyd coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

16 documents, newest first
FirmOpen
483 Jiangsu Hansoh Pharmaceutical Group Co. Ltd. No 5. Dongjin Road, Economic and Technical Development ZoneApr 24, 2026 · Lianyungang, China
483 Shilpa Medicare LimitedNov 21, 2025 · Polepally, Jadcherla, India
483 Lupin LimitedSep 16, 2025 · Nagpur, India
483 Form 483 · FEI 3011248248Sep 27, 2024 · Iskander Puteri, Malaysia
483 Panacea Biotec Pharma Limited Malpur, BaddiOct 12, 2023 · Solan, India
483 Laboratorios Farmaceuticos Rovi S. AMay 19, 2023 · Madrid, Spain
483 INDOCO REMEDIES LIMITEDJan 20, 2023 · Verna, India

About this profile

What does Sandra A. Boyd inspect?

Sandra A. Boyd appears on 16 documents on file covering 14 sites, most often in India.

What do they cite most often?

21 CFR 211.113 (control of microbiological contamination), followed by 21 CFR 211.160 and 21 CFR 211.192.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Sandra A. Boyd is dated Apr 24, 2026.

FDA Investigator Sandra A. Boyd: 483s & Inspections · FDA Intel